Akatsuka K, Hashimoto T, Takeuchi K, Yanagisawa Y
J Toxicol Sci. 1982 Dec;7 Suppl 2:107-21. doi: 10.2131/jts.7.supplementii_107.
Guanabenz (WY-8678) was given to pregnant rats to examine its effects on dams, their fetuses, and offspring. The drug was administered orally to rats at 15, 5 and 1 mg/kg/day from the 7th days of gestation. The vehicle used was 5%-Arabic Gum at dose level of 5 ml/kg, and a control experiment where only the vehicle was administered was also conducted. The results obtained were as follows. 1. In the observation of the dams, the increase of body weight tended to be repressed in the 15 mg/kg group, and body weight decreased in the 30 mg/kg group. 2. The drug produced decreased spontaneous movement, sedation, and lacrimation of red exudate in dams. 3. Half of the 30 mg/kg group had a resorption, but there were no remarkable effects on length of gestation and nursing in the nursing group. 4. The weight of the thymus decreased dose-dependency. 5. No difference was observed in each group in the number of corpora lutea, the number of resorptions, the number of live fetuses, sex ratio, and mean placental weight of the fetuses. The mean body weight of the fetuses decreased in the 30 and among 15 mg/kg groups. 6. In observation of the fetuses, no difference was observed among groups regarding external and visceral malformations. In the skeletal observation, retardation of ossification of the forelimb and hind limb was observed in the 30 and 15 mg/kg groups, and retardation of ossification of the sternebra was observed in the 30 mg/kg group. 7. In observation of the offspring, the number of implantations, the number of live fetuses, delivery rate, and viability rate decrease in the 30 mg/kg group. No difference was observed among groups as to postnatal development symptoms, the faculties of sensation, and emotion. From these results, it is conducted that Guanabenz has no teratogenic potential in rats and the safe dosage levels seems to be below 5 mg/kg/day.
给予孕鼠胍那苄(WY - 8678)以研究其对母鼠、胎儿及后代的影响。从妊娠第7天起,以15、5和1毫克/千克/天的剂量对大鼠口服给药。所用赋形剂为5%阿拉伯胶,剂量为5毫升/千克,同时进行仅给予赋形剂的对照实验。所得结果如下:1. 观察母鼠时,15毫克/千克组体重增加趋势受到抑制,30毫克/千克组体重下降。2. 该药物导致母鼠自发活动减少、出现镇静以及有红色渗出物的流泪现象。3. 30毫克/千克组中有一半出现吸收现象,但对哺乳组的妊娠期和哺乳期无显著影响。4. 胸腺重量呈剂量依赖性下降。5. 各组在黄体数量、吸收数量、活胎数量、性别比例以及胎儿平均胎盘重量方面未观察到差异。30毫克/千克组和15毫克/千克组中胎儿的平均体重下降。6. 观察胎儿时,各组在外在和内脏畸形方面未观察到差异。在骨骼观察中,30毫克/千克组和15毫克/千克组观察到前肢和后肢骨化迟缓,30毫克/千克组观察到胸骨节骨化迟缓。7. 观察后代时,30毫克/千克组的着床数量、活胎数量、分娩率和存活率下降。各组在产后发育症状、感觉能力和情感方面未观察到差异。从这些结果可以得出,胍那苄对大鼠无致畸潜力,安全剂量水平似乎低于5毫克/千克/天。